Osiris Therapeutics (OSIR) Completes Enrollment in Second Prochymal Phase III Trial for Graft vs. Host Disease
Tweet Send to a Friend
Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced that it has successfully completed patient enrollment in its pivotal, Phase III trial evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
